

Saul N Faust

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8813619/publications.pdf>

Version: 2024-02-01

175
papers

28,397
citations

38660

50
h-index

6818

155
g-index

198
all docs

198
docs citations

198
times ranked

43641
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. <i>Pediatric Research</i> , 2023, 93, 207-216.	1.1	10
2	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children in Summer Schools Applying Stringent Control Measures in Barcelona, Spain. <i>Clinical Infectious Diseases</i> , 2022, 74, 66-73.	2.9	26
3	Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e047490.	0.8	6
4	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet</i> , The, 2022, 399, 36-49.	6.3	161
5	Multi-Excitation Raman Spectroscopy for Label-Free, Strain-Level Characterization of Bacterial Pathogens in Artificial Sputum Media. <i>Analytical Chemistry</i> , 2022, 94, 669-677.	3.2	13
6	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. <i>EClinicalMedicine</i> , 2022, 44, 101262.	3.2	87
7	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1238-1244.	2.8	3
8	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. <i>Nature Cancer</i> , 2022, 3, 552-564.	5.7	51
9	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
10	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1131-1141.	4.6	99
11	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. <i>Journal of Infection</i> , 2022, 85, 306-317.	1.7	12
12	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1649.e1-1649.e8.	2.8	20
13	Non-alcoholic fatty liver disease and childhood obesity. <i>Archives of Disease in Childhood</i> , 2021, 106, 3-8.	1.0	57
14	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
15	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	6.3	3,887
16	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 133-141.	2.7	228
17	Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. <i>BMJ Open</i> , 2021, 11, e043012.	0.8	12
18	COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. <i>BMJ Open</i> , 2021, 11, e044899.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
20	Paediatric research in the times of COVID-19. <i>Pediatric Research</i> , 2021, 90, 267-271.	1.1	8
21	Mycotic aneurysm presenting as hip pain and severe anaemia. <i>Archives of Disease in Childhood</i> , 2021, 106, archdischild-2021-321632.	1.0	0
22	P051 Symptoms of COVID-19 and anxiety levels in adult patients receiving b-and ts-DMARDS using an online reporting system. <i>Rheumatology</i> , 2021, 60, .	0.9	0
23	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
24	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
25	Lupus, vaccinations and COVID-19: What we know now. <i>Lupus</i> , 2021, 30, 1541-1552.	0.8	21
26	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	7
27	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2021, 12, 694759.	2.2	22
28	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
29	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
30	Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1417-1426.	6.3	32
31	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
32	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
33	RSV: perspectives to strengthen the need for protection in all infants. <i>Emerging Themes in Epidemiology</i> , 2021, 18, 15.	1.2	16
34	Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2. <i>Frontiers in Medical Technology</i> , 2021, 3, 729658.	1.3	3
35	Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine. <i>JAMA Network Open</i> , 2021, 4, e2128652.	2.8	29
36	The Effect of Haematocrit on Measurement of the Mid-Infrared Refractive Index of Plasma in Whole Blood. <i>Biosensors</i> , 2021, 11, 417.	2.3	3

#	ARTICLE	IF	CITATIONS
37	Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. <i>Clinical and Translational Science</i> , 2021, , .	1.5	1
38	Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1713.	3.8	57
39	Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-72.	1.3	6
40	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519
41	Controlled Human Infection With <i>Bordetella pertussis</i> Induces Asymptomatic, Immunizing Colonization. <i>Clinical Infectious Diseases</i> , 2020, 71, 403-411.	2.9	40
42	Mutations in <i>RPSA</i> and <i>NKX2-3</i> link development of the spleen and intestinal vasculature. <i>Human Mutation</i> , 2020, 41, 196-202.	1.1	9
43	Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 117-125.	1.3	35
44	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. <i>Clinical Infectious Diseases</i> , 2020, 71, 1271-1280.	2.9	7
45	Inflammatory phenotyping predicts clinical outcome in COVID-19. <i>Respiratory Research</i> , 2020, 21, 245.	1.4	72
46	Problem-solving in clinical practice: Persisting respiratory distress in a premature infant. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2020, 106, edpract-2019-317757.	0.3	0
47	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	13.9	1,013
48	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2020, 396, 1345-1352.	6.3	569
49	Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. <i>Vaccine</i> , 2020, 38, 5718-5725.	1.7	2
50	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
51	Immune reconstitution in children following chemotherapy for acute leukemia. <i>EJHaem</i> , 2020, 1, 142-151.	0.4	12
52	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
53	Be on the TEAM Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. <i>BMJ Open</i> , 2020, 10, e037358.	0.8	11
54	COVID-19 in children: current evidence and key questions. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 540-547.	1.3	49

#	ARTICLE	IF	CITATIONS
55	Children are not COVID-19 super spreaders: time to go back to school. <i>Archives of Disease in Childhood</i> , 2020, 105, 618-619.	1.0	169
56	High frequency of paediatric facial nerve palsy due to Lyme disease in a geographically endemic region. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2020, 132, 109905.	0.4	5
57	Experts'™ opinion for improving global adolescent vaccination rates: a call to action. <i>European Journal of Pediatrics</i> , 2020, 179, 547-553.	1.3	12
58	Discovery of Cephalosporin-3-β-Diazoniumdiolates That Show Dual Antibacterial and Antibiofilm Effects against <i>Pseudomonas aeruginosa</i> Clinical Cystic Fibrosis Isolates and Efficacy in a Murine Respiratory Infection Model. <i>ACS Infectious Diseases</i> , 2020, 6, 1460-1479.	1.8	18
59	Congenital syphilis presenting with liver lesions. <i>International Journal of STD and AIDS</i> , 2019, 30, 82-85.	0.5	2
60	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomised controlled Trial (CAP-IT). <i>BMJ Open</i> , 2019, 9, e029875.	0.8	10
61	Protocol for a controlled human infection with genetically modified <i>Neisseria lactamica</i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. <i>BMJ Open</i> , 2019, 9, e026544.	0.8	6
62	Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. <i>BMC Pediatrics</i> , 2019, 19, 50.	0.7	3
63	Diagnosis and treatment of biofilm infections in children. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 505-509.	1.3	2
64	Clinical Presentation of Influenza in Children 6 to 35 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 866-872.	1.1	17
65	Microbial epidemiology and carriage studies for the evaluation of vaccines. <i>Journal of Medical Microbiology</i> , 2019, 68, 1408-1418.	0.7	4
66	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018, 8, 3390.	1.6	34
67	Lyme disease: summary of NICE guidance. <i>BMJ: British Medical Journal</i> , 2018, 361, k1261.	2.4	19
68	Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1479-1482.e6.	1.5	24
69	Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the <scp>UK</scp> towards participation in clinical trials and routine implementation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 330-340.	1.3	13
70	Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 338-349.	2.7	51
71	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. <i>Vaccine</i> , 2018, 36, 2300-2306.	1.7	12
72	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	2.9	51

#	ARTICLE	IF	CITATIONS
73	Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 404-414.	2.7	69
74	Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. <i>Pediatrics</i> , 2018, 142, .	1.0	17
75	Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase $\hat{\Gamma}$ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase $\hat{\Gamma}$ Syndrome Registry. <i>Frontiers in Immunology</i> , 2018, 9, 543.	2.2	137
76	Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing study. <i>Journal of Medical Microbiology</i> , 2018, 67, 1096-1108.	0.7	5
77	Pneumococcal vaccine impacts on the population genomics of non-typeable <i>Haemophilus influenzae</i> . <i>Microbial Genomics</i> , 2018, 4, .	1.0	12
78	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. , 2018, , 18-32.		0
79	Cephalosporin-3 $\hat{\text{A}}$ -Diazoniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable <i>Haemophilus influenzae</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	26
80	Cephalosporin-NO-donor prodrug PYRRO-C3D shows $\hat{\Gamma}$ -lactam - mediated activity against <i>Streptococcus pneumoniae</i> biofilms. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 65, 43-49.	1.2	21
81	The rise and fall of pneumococcal serotypes carried in the PCV era. <i>Vaccine</i> , 2017, 35, 1293-1298.	1.7	68
82	Corticosteroids and infliximab impair the performance of interferon- $\hat{\Gamma}$ 3 release assays used for diagnosis of latent tuberculosis. <i>Thorax</i> , 2017, 72, 946-949.	2.7	43
83	Current and future therapies for <i>Pseudomonas aeruginosa</i> infection in patients with cystic fibrosis. <i>FEMS Microbiology Letters</i> , 2017, 364, .	0.7	85
84	Investigating <i>Bordetella pertussis</i> colonisation and immunity: protocol for an inpatient controlled human infection model. <i>BMJ Open</i> , 2017, 7, e018594.	0.8	26
85	Bone and Joint Infections. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 788-799.	1.1	165
86	Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic <i>Pseudomonas aeruginosa</i> Infection in Cystic Fibrosis. <i>Molecular Therapy</i> , 2017, 25, 2104-2116.	3.7	149
87	Primary ciliary dyskinesia ciliated airway cells show increased susceptibility to <i>Haemophilus influenzae</i> biofilm formation. <i>European Respiratory Journal</i> , 2017, 50, 1700612.	3.1	31
88	Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort. <i>Clinical and Translational Immunology</i> , 2017, 6, e155.	1.7	27
89	Pneumococcal conjugate vaccine implementation in middle-income countries. <i>Pneumonia (Nathan Qld) Tj ETQq1</i> 1.0,784314,rgBT /O	2.5	28
90	Clinical spectrum and features of activated phosphoinositide 3-kinase $\hat{\Gamma}$ syndrome: A large patient cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 597-606.e4.	1.5	377

#	ARTICLE	IF	CITATIONS
91	Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. <i>Microbial Genomics</i> , 2017, 3, e000119.	1.0	26
92	D-methionine interferes with non-typeable <i>Haemophilus influenzae</i> peptidoglycan synthesis during growth and biofilm formation. <i>Microbiology (United Kingdom)</i> , 2017, 163, 1093-1104.	0.7	10
93	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. <i>JCI Insight</i> , 2017, 2, .	2.3	109
94	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. <i>Health Technology Assessment</i> , 2017, 21, 1-164.	1.3	19
95	Authors'™ reply to Eisenhut. <i>BMJ, The</i> , 2016, 355, i5787.	3.0	0
96	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. <i>PLoS ONE</i> , 2016, 11, e0155059.	1.1	4
97	Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies. <i>Scientific Reports</i> , 2016, 6, 35842.	1.6	33
98	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. <i>Vaccine</i> , 2016, 34, 6350-6357.	1.7	0
99	Parallel Evolution in <i>Streptococcus pneumoniae</i> Biofilms. <i>Genome Biology and Evolution</i> , 2016, 8, 1316-1326.	1.1	8
100	<i>Pseudomonas aeruginosa</i> infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 685-697.	1.0	114
101	Precision Molecular Diagnosis Defines Specific Therapy in Combined Immunodeficiency with Megaloblastic Anemia Secondary to MTHFD1 Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1160-1166.e10.	2.0	25
102	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. <i>Pediatrics</i> , 2016, 138, .	1.0	22
103	Suspected sepsis: summary of NICE guidance. <i>BMJ, The</i> , 2016, 354, i4030.	3.0	19
104	Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome. <i>Clinical Immunology</i> , 2016, 171, 38-40.	1.4	28
105	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 835.	3.8	263
106	Comparative Genomics of Carriage and Disease Isolates of <i>Streptococcus pneumoniae</i> Serotype 22F Reveals Lineage-Specific Divergence and Niche Adaptation. <i>Genome Biology and Evolution</i> , 2016, 8, 1243-1251.	1.1	8
107	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 _B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vected Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016, 214, 772-781.	1.9	96
108	Density Distribution of Pharyngeal Carriage of <i>Meningococcus</i> in Healthy Young Adults. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1080-1085.	1.1	13

#	ARTICLE	IF	CITATIONS
109	Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic Tolerance. Antimicrobial Agents and Chemotherapy, 2016, 60, 2456-2466.	1.4	27
110	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <i>P. falciparum</i> Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. Journal of Infectious Diseases, 2016, 213, 1743-1751.	1.9	95
111	Development of X-ray micro-focus computed tomography to image and quantify biofilms in central venous catheter models in vitro. Microbiology (United Kingdom), 2016, 162, 1629-1640.	0.7	7
112	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. Journal of Immunology Research, 2015, 2015, 1-3.	0.9	3
113	Environmental temperature impacts on the performance of QuantiFERON-TB Gold In-Tube assays. Journal of Infection, 2015, 71, 276-280.	1.7	13
114	Evaluation of the Efficacy of ChAd63-MVA Vected Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	1.9	110
115	Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 172-180.	4.6	9
116	Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged ≤ 2 Years: Expert Recommendations on How to Address This Issue. Clinical Infectious Diseases, 2015, 60, 912-918.	2.9	24
117	Intracellular residency of Staphylococcus aureus within mast cells in nasal polyps: A novel observation. Journal of Allergy and Clinical Immunology, 2015, 135, 1648-1651.e5.	1.5	39
118	Fluarix quadrivalent vaccine for influenza. Expert Review of Vaccines, 2015, 14, 1055-1063.	2.0	14
119	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ, The, 2015, 350, h1554-h1554.	3.0	27
120	Current methods for capsular typing of Streptococcus pneumoniae. Journal of Microbiological Methods, 2015, 113, 41-49.	0.7	70
121	Phase I studies: the role of publicly funded academic-healthcare partnerships. BMJ, The, 2015, 351, h3889.	3.0	0
122	Respiratory tract infection associated with seizures. BMJ, The, 2015, 351, h4659.	3.0	1
123	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. Journal of Infection, 2015, 71, 43-52.	1.7	61
124	Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine, 2015, 33, 2015-2021.	1.7	130
125	Paper-based colorimetric enzyme linked immunosorbent assay fabricated by laser induced forward transfer. Biomicrofluidics, 2014, 8, 036502.	1.2	24
126	Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged ≤ 3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. Clinical Infectious Diseases, 2014, 58, 181-187.	2.9	9

#	ARTICLE	IF	CITATIONS
127	New approaches to the treatment of biofilm-related infections. <i>Journal of Infection</i> , 2014, 69, S47-S52.	1.7	82
128	Extremes of Age Are Associated with Indeterminate QuantiFERON-TB Gold Assay Results. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2694-2697.	1.8	60
129	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. <i>Lancet</i> , The, 2014, 384, 2123-2131.	6.3	247
130	Evidence Base for the Use of Corticosteroids in Septic Shock in Children. <i>Critical Care Medicine</i> , 2014, 42, e83-e84.	0.4	3
131	Ciliated Cultures From Patients With Primary Ciliary Dyskinesia Produce Nitric Oxide in Response to <i>Haemophilus influenzae</i> Infection and Proinflammatory Cytokines. <i>Chest</i> , 2014, 145, 668-669.	0.4	14
132	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e91413.	1.1	12
133	Pronounced Metabolic Changes in Adaptation to Biofilm Growth by <i>Streptococcus pneumoniae</i> . <i>PLoS ONE</i> , 2014, 9, e107015.	1.1	42
134	Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis. <i>Vaccine</i> , 2013, 31, 3187-3190.	1.7	13
135	Picture of the Month Quiz Case. <i>JAMA Pediatrics</i> , 2013, 167, 483.	3.3	1
136	Nasal self-swabbing for estimating the prevalence of <i>Staphylococcus aureus</i> in the community. <i>Journal of Medical Microbiology</i> , 2013, 62, 437-440.	0.7	39
137	Stroke in paediatric pneumococcal meningitis: a cross-sectional population-based study. <i>Archives of Disease in Childhood</i> , 2013, 98, 647-649.	1.0	18
138	<i>Clostridium difficile</i> in Children: A Review of Existing and Recently Uncovered Evidence. <i>Advances in Experimental Medicine and Biology</i> , 2013, 764, 57-72.	0.8	4
139	Ribosomal Protein SA Haploinsufficiency in Humans with Isolated Congenital Asplenia. <i>Science</i> , 2013, 340, 976-978.	6.0	176
140	Varicella Zoster Virus Central Nervous System Immune Reconstitution Inflammatory Syndrome Presenting in a Child. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1283-1284.	1.1	7
141	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 675-681.	1.1	5
142	Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine. <i>PLoS ONE</i> , 2013, 8, e64731.	1.1	21
143	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. <i>FASEB Journal</i> , 2012, 26, 907-916.	0.2	50
144	Empirical antibiotics for suspected early neonatal sepsis. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2012, 97, F75.1-F75.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	2.9	224
146	H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 661-669.	2.9	24
147	Prescribing for children – taste and palatability affect adherence to antibiotics: a review. <i>Archives of Disease in Childhood</i> , 2012, 97, 293-297.	1.0	111
148	Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. <i>Expert Review of Vaccines</i> , 2012, 11, 889-902.	2.0	18
149	ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	3.7	196
150	Cephalosporin- β -lactamase diazeniumdiolates: Targeted NO-Donor Prodrugs for Dispersing Bacterial Biofilms. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 9057-9060.	7.2	137
151	Managing bone and joint infection in children. <i>Archives of Disease in Childhood</i> , 2012, 97, 545-553.	1.0	83
152	Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of <i>Streptococcus pneumoniae</i> in young children. <i>Vaccine</i> , 2011, 29, 4400-4404.	1.7	69
153	Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. <i>Vaccine</i> , 2011, 29, 7913-7919.	1.7	35
154	13-valent pneumococcal conjugate vaccine (PCV13). <i>Hum Vaccin</i> , 2011, 7, 1012-1018.	2.4	35
155	Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, e80-e90.	1.1	114
156	POLYMORPHISMS IN PARP, IL1B, IL4, IL10, C1INH, DEFB1, AND DEFA4 IN MENINGOCOCCAL DISEASE IN THREE POPULATIONS. <i>Shock</i> , 2010, 34, 17-22.	1.0	13
157	Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. <i>Emerging Infectious Diseases</i> , 2010, 16, 154-155.	2.0	30
158	Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. <i>Expert Review of Vaccines</i> , 2010, 9, 1385-1398.	2.0	33
159	Linezolid an Oral Treatment Option for Staphylococcal Liver Abscess in Chronic Granulomatous Disease. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1036-1037.	1.1	1
160	Purpura Fulminans. , 2009, , 45-55.		1
161	Expediting clinical trials in a pandemic. <i>BMJ: British Medical Journal</i> , 2009, 339, b4652-b4652.	2.4	6
162	Opa Protein Repertoires of Disease-Causing and Carried Meningococci. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3033-3041.	1.8	15

#	ARTICLE	IF	CITATIONS
163	Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 258-262.	1.3	50
164	Developmental assessment: practice makes perfect. <i>Archives of Disease in Childhood</i> , 2007, 92, 278-278.	1.0	1
165	Emergency management of meningococcal disease: eight years on. <i>Archives of Disease in Childhood</i> , 2007, 92, 283-286.	1.0	56
166	OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH GROUP A STREPTOCOCCAL INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 358-359.	1.1	10
167	Platelet and soluble CD40L in meningococcal sepsis. <i>Intensive Care Medicine</i> , 2006, 32, 1432-1437.	3.9	30
168	Sleeping Sickness in Brothers in London. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 879-881.	1.1	14
169	Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: A retrospective study*. <i>Critical Care Medicine</i> , 2004, 32, 1777-1780.	0.4	76
170	HIV-1 Infection in Children: Current Practice and Future Predictions. <i>Advances in Experimental Medicine and Biology</i> , 2004, 549, 135-148.	0.8	0
171	Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: The role of activated protein C in severe sepsis. <i>Critical Care Medicine</i> , 2001, 29, S75-S77.	0.4	14
172	Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. <i>Critical Care Medicine</i> , 2001, 29, S62-S67.	0.4	85
173	Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis. <i>New England Journal of Medicine</i> , 2001, 345, 408-416.	13.9	704
174	Disseminated intravascular coagulation and purpura fulminans secondary to infection. <i>Best Practice and Research in Clinical Haematology</i> , 2000, 13, 179-197.	0.7	32
175	INFECTIOUS PURPURA FULMINANS: CAUTION NEEDED IN THE USE OF PROTEIN C. <i>British Journal of Haematology</i> , 1999, 106, 253-253.	1.2	3